These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29727311)

  • 21. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
    Chakravarthy A; Abrams RA; Yeo CJ; Korman LT; Donehower RC; Hruban RH; Zahurek ML; Grochow LB; O'Reilly S; Hurwitz H; Jaffee EM; Lillemoe KD; Cameron JL
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1089-96. PubMed ID: 11072167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
    Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
    Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS
    J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.
    Tzeng CW; Fleming JB; Lee JE; Xiao L; Pisters PW; Vauthey JN; Abdalla EK; Wolff RA; Varadhachary GR; Fogelman DR; Crane CH; Balachandran A; Katz MH
    Ann Surg Oncol; 2012 Jun; 19(6):2045-53. PubMed ID: 22258816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
    Cooper AB; Holmes HM; des Bordes JK; Fogelman D; Parker NH; Lee JE; Aloia TA; Vauthey JN; Fleming JB; Katz MH
    J Am Coll Surg; 2014 Jul; 219(1):111-20. PubMed ID: 24856952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resected pancreatic adenocarcinoma: An Asian institution's experience.
    Ng KYY; Chow EWX; Jiang B; Lim C; Goh BKP; Lee SY; Teo JY; Tan DMY; Cheow PC; Ooi LLPJ; Chow PKH; Lee JJX; Kam JH; Koh YX; Jeyaraj PR; Tan EK; Choo SP; Chan CY; Chung AYF; Tai D
    Cancer Rep (Hoboken); 2021 Oct; 4(5):e1393. PubMed ID: 33939335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
    Rashid OM; Pimiento JM; Gamenthaler AW; Nguyen P; Ha TT; Hutchinson T; Springett G; Hoffe S; Shridhar R; Hodul PJ; Johnson BL; Illig K; Armstrong PA; Centeno BA; Fulp WJ; Chen DT; Malafa MP
    Ann Surg Oncol; 2016 Apr; 23(4):1371-9. PubMed ID: 26661409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
    Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
    Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
    Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer.
    Liu Z; Luo G; Guo M; Jin K; Xiao Z; Liu L; Liu C; Xu J; Ni Q; Long J; Yu X
    Pancreatology; 2015; 15(3):253-8. PubMed ID: 25921232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world impact of availability of adjuvant therapy on outcomes in patients with resected pancreatic adenocarcinoma: a Canadian Cancer Agency experience.
    Kim C; Owen D; Gill S
    Am J Clin Oncol; 2012 Jun; 35(3):212-5. PubMed ID: 21358297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The addition of radiation to chemotherapy does not improve outcome when compared to chemotherapy in the treatment of resected pancreas cancer: the results of a single-institution experience.
    Martin LK; Luu DC; Li X; Muscarella P; Ellison EC; Bloomston M; Bekaii-Saab T
    Ann Surg Oncol; 2014 Mar; 21(3):862-867. PubMed ID: 24046122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
    Regine WF; Winter KA; Abrams R; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Rich TA; Willett CG
    Ann Surg Oncol; 2011 May; 18(5):1319-26. PubMed ID: 21499862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?
    Bednar F; Zenati MS; Steve J; Winters S; Ocuin LM; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
    Ann Surg Oncol; 2017 May; 24(5):1406-1413. PubMed ID: 27896518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results.
    Sinn M; Liersch T; Riess H; Gellert K; Stübs P; Waldschmidt D; Lammert F; Maschmeyer G; Bechstein W; Bitzer M; Denzlinger C; Hofheinz R; Lindig U; Ghadimi M; Hinke A; Striefler JK; Pelzer U; Bischoff S; Bahra M; Oettle H
    Eur J Cancer; 2020 Oct; 138():172-181. PubMed ID: 32890813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.
    Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA
    Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial.
    Katz MH; Wolff R; Crane CH; Varadhachary G; Javle M; Lin E; Evans DB; Lee JE; Fleming JB; Pisters PW
    Ann Surg Oncol; 2011 Dec; 18(13):3615-22. PubMed ID: 21701927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer.
    Merrell KW; Haddock MG; Quevedo JF; Harmsen WS; Kendrick ML; Miller RC; Hallemeier CL
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):561-70. PubMed ID: 26867884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum.
    Coia L; Hoffman J; Scher R; Weese J; Solin L; Weiner L; Eisenberg B; Paul A; Hanks G
    Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):161-7. PubMed ID: 8083109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data.
    Chikhladze S; Lederer AK; Kousoulas L; Reinmuth M; Sick O; Fichtner-Feigl S; Wittel UA
    World J Surg Oncol; 2019 Nov; 17(1):185. PubMed ID: 31706323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.